CLUSTER HEADACHE MARKET ANALYSIS

Cluster Headache Market Size and Trends

Global cluster headache market is estimated to be valued at USD 422.2 Mn in 2024 and is expected to reach USD 644.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031. Cluster headache is a neurological disorder characterized by severe pain on one side of the head. Currently available treatment options for this disease provide only symptomatic relief.

To learn more about this report, request sample copy

The market growth is driven by increasing prevalence of cluster headaches and the need for more effective therapeutics. Many biopharmaceutical companies are actively researching novel therapies such as monoclonal antibodies and calcitonin gene-related peptide (CGRP) antagonists to provide improved treatment outcomes.

New Product Launches

Global cluster headache market has witnessed significant growth due to numerous new product launches that have expanded treatment options for people with cluster headache. Pharmaceutical companies have invested heavily in developing novel drug delivery mechanisms and medications that target cluster headaches in new ways. This increased focus on innovation has resulted in more effective acute and preventative therapies. Some of the major new product categories to emerge include novel oral treatments, nerve stimulators, and injectable medications. Oral treatments such as ditans and lasmiditan provide acute options beyond traditional triptans, allowing patients to avoid potential drug interactions or side effects. Sprays such as zolmitriptan nasal have also extended non-oral dosing possibilities. Preventative treatments have expanded. The U.S. FDAapproved the first dedicated monoclonal antibody galcanezumab-gnlm in 2020, according to the Food and Drug Administration.

 Meanwhile, non-drug devices like the gammaCore Sapphire have provided new hope to patients who find oral medications insufficient through non-invasive vagus nerve stimulation.

Increasing Prevalence of Cluster Headache

Cluster headache is a severe primary headache disorder that is characterized by intense pain on one side of the head. There has been increase in cases of this disease due to greater awareness and accurate diagnosis of the condition. Earlier, cluster headache was often misdiagnosed as migraine or sinus headache due to its excruciating nature localized to one side of the head. However, with enhancement in doctors' understanding of its distinctive symptoms like periodic attacks, Horner's syndrome, and others, more patients with actual cluster headache are being identified now. Moreover, improved medical surveillance and longitudinal epidemiological research have enabled getting a clearer picture of how widespread this condition is. Several population-based studies conducted in the recent decades across countries like U.S., U.K. Canada, Italy, Norway, and others have estimated the point prevalence of cluster headache to be anywhere between 50 to 300 per 100,000 persons. The higher prevalence numbers have been reported from Norway, suggesting a possible genetic role. The disease mainly affects the adult population between 20-50 years of age with a significant male predisposition. For Instance In April 2020, according to an research article published by BMC (BioMed Central), a systematic review and meta-analysis was conducted following the guidelines of the preferred reporting items for systematic reviews and meta-analyses protocols (PRISMA-P). The study revealed that approximately 6.27% of patients with cluster headache had a family history, with an overall I2 of 73%.